SARS-CoV-2 M-pro inhibitors with antiviral activity in a transgenic mouse model

被引：324

作者：

Qiao, Jingxin ^{[1
]}

Li, Yue-Shan ^{[1
]}

Zeng, Rui ^{[1
]}

Liu, Feng-Liang ^{[2
,3
]}

Luo, Rong-Hua ^{[2
,3
]}

Huang, Chong ^{[1
]}

Wang, Yi-Fei ^{[4
]}

Zhang, Jie ^{[1
]}

Quan, Baoxue ^{[1
]}

Shen, Chenjian ^{[1
]}

Mao, Xin ^{[1
]}

Liu, Xinlei ^{[1
]}

Sun, Weining ^{[1
]}

Yang, Wei ^{[1
]}

Ni, Xincheng ^{[1
]}

Wang, Kai ^{[1
]}

Xu, Ling ^{[2
,3
]}

Duan, Zi-Lei ^{[2
,3
]}

Zou, Qing-Cui ^{[3
]}

Zhang, Hai-Lin ^{[3
,5
]}

Qu, Wang ^{[3
]}

Long, Yang-Hao-Peng ^{[3
]}

Li, Ming-Hua ^{[3
]}

Yang, Rui-Cheng ^{[1
]}

Liu, Xiaolong ^{[1
]}

You, Jing ^{[1
]}

Zhou, Yangli ^{[1
]}

Yao, Rui ^{[1
]}

Li, Wen-Pei ^{[1
]}

Liu, Jing-Ming ^{[1
]}

Chen, Pei ^{[4
]}

Liu, Yang ^{[1
]}

Lin, Gui-Feng ^{[1
]}

Yang, Xin ^{[1
]}

Zou, Jun ^{[1
]}

Li, Linli ^{[4
]}

Hu, Yiguo ^{[1
]}

Lu, Guang-Wen ^{[1
]}

Li, Wei-Min ^{[1
]}

Wei, Yu-Quan ^{[1
]}

Zheng, Yong-Tang ^{[2
,3
]}

Lei, Jian ^{[1
,6
]}

Yang, Shengyong ^{[1
]}

机构：

[1] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China

[2] Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, Kunming Inst Zool, Kunming 650223, Yunnan, Peoples R China

[3] Chinese Acad Sci, Ctr Biosafety Megasci, Kunming Inst Zool, Kunming Natl High Level Biosafety Res Ctr Nonhuma, Kunming 650107, Yunnan, Peoples R China

[4] Sichuan Univ, West China Sch Pharm, Key Lab Drug Targeting & Drug Delivery Syst, Minist Educ, Chengdu 610041, Sichuan, Peoples R China

[5] Chinese Acad Sci, Kunming Inst Zool, State Key Lab Genet Resources & Evolut, Kunming 650223, Yunnan, Peoples R China

[6] Sichuan Univ, West China Hosp, Natl Clin Res Ctr Geriatr, Chengdu 610041, Sichuan, Peoples R China

来源：

SCIENCE | 2021年 / 371卷 / 6536期

基金：

国家重点研发计划; 中国国家自然科学基金;

关键词：

3CL PROTEASE INHIBITORS; SARS; DISCOVERY; DESIGN;

D O I：

10.1126/science.abf1611

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continually poses serious threats to global public health. The main protease (M-pro) of SARS-CoV-2 plays a central role in viral replication. We designed and synthesized 32 new bicycloproline-containing M-pro inhibitors derived from either boceprevir or telaprevir, both of which are approved antivirals. All compounds inhibited SARS-CoV-2 M-pro activity in vitro, with 50% inhibitory concentration values ranging from 7.6 to 748.5 nM. The cocrystal structure of M-pro in complex with MI-23, one of themost potent compounds, revealed its interactionmode. Two compounds (MI-09 and MI-30) showed excellent antiviral activity in cell-based assays. In a transgenic mouse model of SARS-CoV-2 infection, oral or intraperitoneal treatment withMI-09 or MI-30 significantly reduced lung viral loads and lung lesions. Both also displayed good pharmacokinetic properties and safety in rats.

引用

页码：1374 / +

页数：89

共 50 条

[1] Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition
Gimeno, Aleix
Mestres-Truyol, Julia
Jose Ojeda-Montes, Maria
Macip, Guillem
Saldivar-Espinoza, Bryan
Cereto-Massague, Adria
Pujadas, Gerard
Garcia-Vallve, Santiago
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (11)
[2] Impact of Warhead Modulations on the Covalent Inhibition of SARS-CoV-2 M-pro Explored by QM/MM Simulations
Marti, Sergio
Arafet, Kemel
Lodola, Alessio
Mulholland, Adrian J.
Swiderek, Katarzyna
Moliner, Vicent
ACS CATALYSIS, 2022, 12 (01) : 698 - 708
[3] Synthesis and In Silico Docking Study towards M-Pro of Novel Heterocyclic Compounds Derived from Pyrazolopyrimidinone as Putative SARS-CoV-2 Inhibitors
Horchani, Mabrouk
Heise, Niels, V
Csuk, Rene
Ben Jannet, Hichem
Harrath, Abdel Halim
Romdhane, Anis
MOLECULES, 2022, 27 (16):
[4] CFTR Inhibitors Display In Vitro Antiviral Activity against SARS-CoV-2
Lagni, Anna
Lotti, Virginia
Diani, Erica
Rossini, Giada
Concia, Ercole
Sorio, Claudio
Gibellini, Davide
CELLS, 2023, 12 (05)
[5] Antiviral Activity of Amiodarone in SARS-CoV-2 Disease
Bilek, Radovan
Danzig, Vilem
Grimmichova, Tereza
PHYSIOLOGICAL RESEARCH, 2022, 71 (06) : 869 - 875
[6] Nonpeptidic Irreversible Inhibitors of SARS-CoV-2 Main Protease with Potent Antiviral Activity
Oneto, Angelo
Al Hamwi, Ghazl
Schaekel, Laura
Krueger, Nadine
Sylvester, Katharina
Petry, Marvin
Abu Shamleh, Rasha
Pillaiyar, Thanigaimalai
Claff, Tobias
Schiedel, Anke C.
Straeter, Norbert
Guetschow, Michael
Mueller, Christa E.
JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (17) : 14986 - 15011
[7] Structural and virologic mechanism of the emergence of resistance to M pro inhibitors in SARS-CoV-2
Hattori, Shin-ichiro
Bulut, Haydar
Hayashi, Hironori
Kishimoto, Naoki
Takamune, Nobutoki
Hasegawa, Kazuya
Furusawa, Yuri
Yamayoshi, Seiya
Murayama, Kazutaka
Tamamura, Hirokazu
Li, Mi
Wlodawer, Alexander
Kawaoka, Yoshihiro
Misumi, Shogo
Mitsuya, Hiroaki
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2024, 121 (37)
[8] A mouse model of SARS-CoV-2 transmission
Jorge Ferreira
Lab Animal, 2023, 52 : 143 - 143
[9] A mouse model of SARS-CoV-2 transmission
Ferreira, Jorge
LAB ANIMAL, 2023, 52 (07) : 143 - 143
[10] CREATION OF A TRANSGENIC MOUSE MODEL TO STUDY THE SARS-COV-2 EFFECT ON THE PATHOGENESIS OF ATHEROSCLEROSIS
Kubekina, M.
Ilchuk, L.
Bruter, A.
Deykin, A.
ATHEROSCLEROSIS, 2021, 331 : E81 - E81

← 1 2 3 4 5 →